Evidence map›Paper›PMID 29282221›Full record

ArticleCancer research2018

Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.

Weikun Xiao, Rongyu Zhang, Alireza Sohrabi, Arshia Ehsanipour, Songping Sun, Jesse Liang, Christopher M Walthers, Lisa Ta, David A Nathanson, Stephanie K Seidlits

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 96 citations in OpenAlex.

  1. Biomimetic Scaffold-Based 3D Models for Decoding Cancer Biology and Advancing Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Article
  4. Hydrogel Microdroplet Based Glioblastoma Drug Screening Platform.Journal of biomedical materials research. Part A · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Hydrogel microdroplet based glioblastoma drug screening platform.bioRxiv : the preprint server for biology · 2025
    Article
  9. Review
  10. Mouse Models of Metastasis and Dormancy.Cold Spring Harbor perspectives in medicine · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Weikun XiaoDepartment of Bioengineering, University of California, Los Angeles, California.
Rongyu ZhangDepartment of Bioengineering, University of California, Los Angeles, California.
Alireza SohrabiDepartment of Bioengineering, University of California, Los Angeles, California.
Arshia EhsanipourDepartment of Bioengineering, University of California, Los Angeles, California.
Songping SunDepartment of Bioengineering, University of California, Los Angeles, California.
Jesse LiangDepartment of Bioengineering, University of California, Los Angeles, California.
Christopher M WalthersDepartment of Bioengineering, University of California, Los Angeles, California.
Lisa TaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California.
David A NathansonDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California.
Stephanie K SeidlitsDepartment of Bioengineering, University of California, Los Angeles, California. seidlits@ucla.edu.
University of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Targeting metabolic vulnerabilities in glioblastomaR01CA213133 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NATHANSON, DAVID A. · 2017 to 2021
$2.5M
Engineered microenvironments as biomimetic culture platforms for studying the role of brain extracellular matrix in acquisition of resistance to EGFR inhibition across multiple biological scalesR21NS093199 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NATHANSON, DAVID A., SEIDLITS, STEPHANIE KRISTIN · 2015 to 2016
$424k
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA213133NINDS NIH HHS R21 NS093199
6 · The paper itself

Abstract

Glioblastoma (GBM) tumors exhibit potentially actionable genetic alterations against which targeted therapies have been effective in treatment of other cancers. However, these therapies have largely failed in GBM patients. A notable example is kinase inhibitors of EGFR, which display poor clinical efficacy despite overexpression and/or mutation of EGFR in >50% of GBM. In addressing this issue, preclinical models may be limited by the inability to accurately replicate pathophysiologic interactions of GBM cells with unique aspects of the brain extracellular matrix (ECM), which is relatively enriched in hyaluronic acid (HA) and flexible. In this study, we present a brain-mimetic biomaterial ECM platform for 3D culturing of patient-derived GBM cells, with improved pathophysiologic properties as an experimental model. Compared with orthotopic xenograft assays, the novel biomaterial cultures we developed better preserved the physiology and kinetics of acquired resistance to the EGFR inhibition than gliomasphere cultures. Orthogonal modulation of both HA content and mechanical properties of biomaterial scaffolds was required to achieve this result. Overall, our findings show how specific interactions between GBM cell receptors and scaffold components contribute significantly to resistance to the cytotoxic effects of EGFR inhibition.

Indexed as

Drug Resistance, NeoplasmAnimalsApoptosisBiocompatible MaterialsBiomarkers, TumorBiomimeticsBrain NeoplasmsCell Culture TechniquesCell ProliferationErbB ReceptorsExtracellular MatrixGlioblastomaHumansHyaluronic AcidHydrogelsMiceBiocompatible MaterialsBiomarkers, TumorEGFR protein, humanErbB ReceptorsHyaluronic AcidHydrogelsProtein Kinase Inhibitors

Identifiers

PMID29282221
PMCPMC5935550
OpenAlexW2778160201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.